枸橼酸莫沙必利治疗帕金森综合征患者消化道功能紊乱的疗效

doi:10.13481/j.1671-587x.20170125

Abstract

Abstract:

Objective: To explore the therapeutic effect of mosapride citrate on lower gastrointestinal tract function disorder of the patients with Parkinson's syndrome, and to clarify its mechnism.Methods: A total of 29 patients with Parkinson's syndrome complicated with lower gastrointestinal tract function disorder (20 men,9 women; mean age, 68.7 years) were selected and treated with 15 mg of mosapride citrate 3 times a day,by oral for 3 months. The colonic transit time (CTT) of the patients was detected.and rectoanal videomanometry was used to measure the pressures and capacities in colon of the patients at different periods.Results: The defecation diffculties were improved after treated with mosapride citrate. Compared with before treatment, the mean CTT of the patients after treatment was shorten (P<0.05), expecially in the left colon (P<0.01). Compared with before treatment, mosapride augmented the amplitude in rectal contraction after treatment (P<0.05) and lessened the volume of postdefecation residuals.Conclusion: As a kind of 5-HT4 receptor agonist and 5-HT3 receptor antagonistic agent, mosapride citrate can promote the lower gastrointestinal tract motility and ameliorate constipation in the Parkinson's syndrome patients.

Key words: lower gastrointestinal tract disorder, mosapride citrate, Parkinson's syndrome

CLC Number:

R574.4

LIU Yang, LIU Zhi, LI Fenge, KONG Fanli. Therapeutic effect of mosapride citrate on gastrointestinal tract function disorder of patients with Parkinson's syndrome[J].Journal of Jilin University Medicine Edition, 2017, 43(01): 125-129.

References

[1] Barboza JL, Okun MS, Moshiree B. The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients withParkinson's disease[J]. Expert Opin Pharmacother,2015,16(16):2449-2464.
[2] Jost WH, Schimrigk K. Long-term results with cisapride in Parkinson's disease[J]. Mov Disord, 1997,12(3):423-425.
[3] Kii Y, Nakatsuji K, Nose I, et al. Effects of 5-HT(4) receptor agonists, cisapride and mosapride citrate on electrocardiogram in anaesthetized rats and guinea-pigs and conscious cats[J]. Pharmacol Toxicol, 2001,89(2):96-103.
[4] Asakawa H, Hayashi I, Fukui T, et al. Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy[J]. Diabetes Res Clin Pract,2003,61(3):175-182.
[5] Hallerbäck BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia:a placebo-controlled, randomized study[J]. Aliment Pharmacol Ther, 2002,16(5):959-967.
[6] Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy[J]. J Auton Nerv Syst, 1998,74(2/3):189-192.
[7] Devroede G. Radiopaque marker measurement of colorectal transit.In:Schuster MM ed, Atlas of gastrointestinal motility in health and disease[M]. Baltimore:Williams and Wilkins, 1993:57-75.
[8] Cersosimo MG Gastrointestinal biopsies for the diagnosis of alpha-synuclein pathology in Parkinson's disease[J]. Gastroenterol Res Pract, 2015,2015:1-6.
[9] Tuladhar BR, Ge L, Naylor RJ. 5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum[J]. Br J Pharmacol, 2003,138(7):1210-1214.
[10] Ashraf W, Pfeiffer RF, Park F, et al. Constipation in Parkinson's disease; objective assessment and response to psyllium[J]. Mov Disord, 1997,12(6):946-951.
[11] Bassotti G, Maggio D, Battaglia E, et al. Manometric investigation of anorectal function in early and late stage Parkinson's disease[J]. J Neurol Neurosurg Psychiatr, 2000,68(6):768-770.
[12] Sakakibara R, Odaka T, Uchiyama T, et al. Colonic transit time,sphincter EMG and rectoanal videomanometry in multiple system atrophy[J]. Mov Disord, 2004,19(8):924-929.
[13] Kupsky WJ, Grimes MM, Sweeting J, et al. Parkinson's disease and megacolon; concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells[J]. Neurology, 1987,37(7):1253-1255.
[14] Daniel SE. The neuropathology and neurochemistry of multiple system atrophy.[A]Bannister R, Mathias CJ, editors. Autonomic failure[M].3rd ed. Oxford:Oxford Medical Publications, 1992:564-585.
[15] Neira WD, Sanchez V, Mena MA, et al. The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease[J]. Mov Disord, 1995,10(1):66-70.
[16] Kadowaki M, Wang XO, Shimatani H, et al.5-HT4 receptor enhances the propulsive power of the peristaltic reflex in the rat distal colon[J]. Auton Neurosci,2002,99(1):62-65.
[17] Shimatani H, Kojima Y, Kadowaki M, et al. A 5-HT4 agonist mosapride enhances rectorectal and rectoanal reflexes in guinea pigs[J]. Am J Physiol Gastrointest Liver Physiol, 2003,285(2):G389-G395.
[18] Iida H, Inada H, Tanaka H, et al.Effects of antiemetic drugs in combination with a dopamine receptor agonist, pergolide, on Parkinson's disease; a comparison between domperidone and mosapride[J]. Neurol Therap, 2002,19(3):57-62.

Therapeutic effect of mosapride citrate on gastrointestinal tract function disorder of patients with Parkinson's syndrome

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Metrics

Comments

Recommended 0